Acumen Pharmaceuticals (ABOS) Liabilities and Shareholders Equity (2020 - 2026)

Acumen Pharmaceuticals' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $133.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 34.65% year-over-year to $133.6 million; the TTM figure through Mar 2026 stood at $570.6 million (down 42.91% YoY), while the FY2025 annual figure was $122.8 million, down 48.6% from the prior year.
• Liabilities and Shareholders Equity came in at $133.6 million for Q1 2026 at Acumen Pharmaceuticals, up from $122.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $310.1 million in Q4 2023 to a low of $122.8 million in Q4 2025.
• A 5-year average of $215.5 million and a median of $204.5 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 190.2% in 2022 and plunged 48.6% in 2025, its largest moves.
• Acumen Pharmaceuticals' Liabilities and Shareholders Equity stood at $196.6 million in 2022, then jumped by 57.75% to $310.1 million in 2023, then fell by 22.94% to $239.0 million in 2024, then sank by 48.6% to $122.8 million in 2025, then gained by 8.79% to $133.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $133.6 million, $122.8 million, and $142.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison